CCDC93常见变异通过调节LDL受体胞内转运降低心梗风险
细胞和小鼠实验显示该变异增加CCDC93蛋白稳定性,过表达人CCDC93可降低小鼠血浆LDL-c,而CCDC93敲除减少细胞膜LDLR水平及LDL摄取。
要点
- CCDC93 p.Pro228Leu与rs10490626强连锁(r²>0.96),呈剂量依赖性降低LDL-c(P-trend 2.5×10⁻⁶至8.0×10⁻⁹)。
- 该变异与心肌梗死风险降低(P-trend 0.04-0.002)及心血管死亡风险降低(P-trend 0.005-0.004)相关。
- 机制上该变异增加CCDC93蛋白稳定性,通过影响LDLR再循环调节血浆LDL-c水平。
核心结论
- CCDC93常见变异与较低LDL-c水平、较低心肌梗死风险和较低心血管死亡风险相关。
研究设计与样本
- 在普通人群(哥本哈根普通人群研究和哥本哈根城市心脏研究)中纳入超过107 000名个体进行遗传变异关联分析。
- 在细胞和小鼠中研究CCDC93功能,并在包含194 000至超过700 000名参与者的荟萃分析中验证LDL-c、冠心病和心肌梗死风险结果。
主要发现
- INSIG2位点lead变异rs10490626与附近基因表达变化无关,但属于一个排除INSIG2的遗传区块。
- CCDC93 p.Pro228Leu与rs10490626强连锁不平衡(r²>0.96)。
- 在普通人群中,CCDC93 p.Pro228Leu单独及合并分析均呈剂量依赖性关联较低LDL-c(P-trend 2.5×10⁻⁶至8.0×10⁻⁹)、较低心肌梗死风险(P-trend 0.04-0.002)和较低心血管死亡风险(P-trend 0.005-0.004)。
- 该变异增加CCDC93蛋白稳定性;过表达人CCDC93可降低小鼠血浆LDL-c;CCDC93敲除因细胞膜LDLR水平降低而减少LDL摄取。
临床怎么用
- 该变异可能作为评估心肌梗死和心血管死亡遗传风险的候选标志物,但尚需进一步临床验证。
- CCDC93调控LDLR再循环的机制为降脂治疗提供了潜在新靶点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Genome-wide association studies have previously identified INSIG2 as a candidate gene for plasma low-density lipoprotein cholesterol (LDL-c). However, we suspect a role for CCDC93 in the same locus because of its involvement in the recycling of the LDL-receptor (LDLR). METHODS AND RESULTS: Characterization of the INSIG2 locus was followed by studies in over 107 000 individuals from the general population, the Copenhagen General Population Study and the Copenhagen City Heart Study, for associations of genetic variants with plasma lipids levels, with risk of myocardial infarction (MI) and with cardiovascular mortality. CCDC93 was furthermore studied in cells and mice. The lead variant of the INSIG2 locus (rs10490626) is not associated with changes in the expression of nearby genes but is a part of a genetic block, which excludes INSIG2. This block includes a coding variant in CCDC93 p.Pro228Leu, which is in strong linkage disequilibrium with rs10490626 (r2 > 0.96). In the general population, separately and combined, CCDC93 p.Pro228Leu is dose-dependently associated with lower LDL-c (P-trend 2.5 × 10-6 to 8.0 × 10-9), with lower risk of MI (P-trend 0.04-0.002) and lower risk of cardiovascular mortality (P-trend 0.005-0.004). These results were validated for LDL-c, risk of both coronary artery disease and MI in meta-analyses including from 194 000 to >700 000 participants. The variant is shown to increase CCDC93 protein stability, while overexpression of human CCDC93 decreases plasma LDL-c in mice. Conversely, CCDC93 ablation reduces LDL uptake as a result of reduced LDLR levels at the cell membrane. CONCLUSION: This study provides evidence that a common variant in CCDC93, encoding a protein involved in recycling of the LDLR, is associated with lower LDL-c levels, lower risk of MI and cardiovascular mortality.
引用
- Rimbert A, Dalila N, Wolters JC, et al. A common variant in CCDC93 protects against myocardial infarction and cardiovascular mortality by regulating endosomal trafficking of low-density lipoprotein receptor. Eur Heart J. 2020. PMID: 31630160. doi:10.1093/eurheartj/ehz727
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。